Abbott Laboratories Stock

Abbott Laboratories (ABT) – FY2025 Annual Report

Abbott closed 2025 with revenue of roughly $44.3 billion, up about 5.7% year-over-year, alongside net income of $6.5 billion. On the surface this suggests steady operational momentum, but the headline that immediately stands out is the roughly 51% drop in net income from the prior year. This decline appears to be almost entirely an artifact of comparison rather than a deterioration in the underlying business, since 2024 benefited from an unusually large tax benefit rather than exceptional operating strength.

The distinction between operating performance and reported earnings seems particularly important this year. Operating earnings actually rose meaningfully, from around $6.8 billion to $8.1 billion, and operating margin expanded to roughly 18.2% from 16.3%. The apparent profit collapse traces back to the tax line: 2024 recorded a $6.4 billion tax benefit, whereas 2025 carried a more conventional $1.9 billion tax expense. Read this way, the business may in fact be strengthening operationally even as the reported bottom line looks weaker. Segment trends reinforce this—Medical Devices continued its notable climb, with Diabetes Care revenue reaching roughly $8.0 billion, while Diagnostics kept contracting as COVID-19 testing revenue faded to under $300 million from $747 million, dragging the segment's operating earnings lower.